TXG 10x Genomics Inc
Price (delayed)
$8.31
Market cap
$1.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.52
Enterprise value
$754.87M
10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin
Highlights
TXG's EPS is up by 30% year-on-year
The company's net income rose by 28% YoY
TXG's equity is down by 4.2% year-on-year
10x Genomics's revenue has decreased by 3% from the previous quarter
Key stats
What are the main financial stats of TXG
Market
Valuations
Earnings
Shares outstanding
122.3M
Market cap
$1.02B
Enterprise value
$754.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.42
Price to sales (P/S)
1.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.24
Revenue
$610.79M
Gross profit
$414.48M
Operating income
-$194.56M
Net income
-$182.63M
EBIT
-$177.7M
EBITDA
-$133.99M
Free cash flow
-$5.73M
Per share
Balance sheet
Liquidity
EPS
-$1.52
EPS diluted
-$1.52
Free cash flow per share
-$0.05
Book value per share
$5.87
Revenue per share
$5.07
TBVPS
$7.46
Total assets
$918.64M
Total liabilities
$208.5M
Debt
$82.61M
Equity
$710.13M
Working capital
$466.75M
Debt to equity
0.12
Current ratio
4.97
Quick ratio
4.09
Net debt/EBITDA
1.95
Margins
Efficiency
Dividend
EBITDA margin
-21.9%
Gross margin
67.9%
Net margin
-29.9%
Operating margin
-31.9%
Return on assets
-19.7%
Return on equity
-25.4%
Return on invested capital
-34.8%
Return on capital employed
-22.2%
Return on sales
-29.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TXG stock price
How has the 10x Genomics stock price performed over time
Intraday
3.68%
1 week
10.65%
1 month
-20.02%
1 year
-69.8%
YTD
-42.13%
QTD
-4.81%
Financial performance
How have 10x Genomics's revenue and profit performed over time
Revenue
$610.79M
Gross profit
$414.48M
Operating income
-$194.56M
Net income
-$182.63M
Gross margin
67.9%
Net margin
-29.9%
The company's net income rose by 28% YoY
TXG's operating income is up by 27% year-on-year and by 2.7% since the previous quarter
10x Genomics's net margin has increased by 27% YoY but it has decreased by 3.1% QoQ
10x Genomics's operating margin has increased by 26% YoY
Growth
What is 10x Genomics's growth rate over time
Valuation
What is 10x Genomics stock price valuation
P/E
N/A
P/B
1.42
P/S
1.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.24
TXG's EPS is up by 30% year-on-year
The P/B is 88% below the 5-year quarterly average of 11.9 and 64% below the last 4 quarters average of 3.9
TXG's equity is down by 4.2% year-on-year
The stock's price to sales (P/S) is 92% less than its 5-year quarterly average of 21.8 and 64% less than its last 4 quarters average of 4.5
10x Genomics's revenue has decreased by 3% from the previous quarter
Efficiency
How efficient is 10x Genomics business performance
TXG's ROS is up by 28% year-on-year but it is down by 4.3% since the previous quarter
TXG's ROA is up by 24% YoY
The ROE has grown by 23% YoY
The return on invested capital is up by 15% year-on-year but it has declined by 2.7% since the previous quarter
Dividends
What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TXG.
Financial health
How did 10x Genomics financials performed over time
10x Genomics's total liabilities has decreased by 7% YoY and by 3% QoQ
The current ratio has grown by 6% YoY
10x Genomics's debt is 88% lower than its equity
10x Genomics's debt has decreased by 13% YoY and by 3.8% QoQ
10x Genomics's debt to equity has decreased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.